Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B by Sonneveld, Milan J. & Janssen, Harry L. A.
Pros and Cons of Peginterferon Versus Nucleos(t)ide
Analogues for Treatment of Chronic Hepatitis B
Milan J. Sonneveld & Harry L. A. Janssen
Published online: 15 April 2010
# The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract The emergence of new and more potent
treatment options has markedly changed the treatment
landscape of chronic hepatitis B. Both peginterferon and
nucleos(t)ide analogues have considerable advantages
and limitations, and current treatment guidelines refrain
from clearly suggesting a first-line treatment option.
Peginterferon offers the advantage of higher sustained
response rates in both hepatitis B early antigen (HBeAg)-
positive and HBeAg-negative patients, at the price of
considerable side effects and high costs. Nucleos(t)ide
analogues offer easy daily oral dosing, and newly
registered agents can maintain viral suppression for
prolonged treatment duration. However, relapse is com-
mon after therapy discontinuation and extended therapy
therefore often necessary. Prolonged treatment with
nucleos(t)ide analogues may enhance chances of viro-
logic and serologic response at the potential cost of the
emergence of viral resistance and side effects. Baseline
and on-treatment prediction of response may help select
patients for peginterferon therapy and can aid individu-





Chronic hepatitis B is a major health problem affecting more
than 350 million people worldwide. Prolonged infection with
thehepatitisBvirusmayresultinsevereliver-relatedmorbidity
and mortality, so treatment of chronic hepatitis B is indicated in
patients with active liver inflammation [1, 2]. The introduction
of nucleos(t)ide analogues (NA) changed the landscape of
chronic hepatitis B management, because they have proven, at
least in the short term, to be a safe and effective alternative to
interferon (IFN). However, interest in IFN-based treatment
regimens was renewed after the introduction of a pegylated
form of standard interferon-α (PEG-IFN), which has better
pharmacokinetic properties and higher antiviral potency than
regular IFN [3]. Current guidelines recognize five NA for the
treatment of chronic hepatitis B (lamivudine, telbivudine,
adefovir, entecavir, and tenofovir), along with two formula-
tions of PEG-IFN (peginterferon α-2a and α-2b) [4]. Both
treatment modalities have proven to be effective, but clear
recommendations as to which treatment strategy (NA or PEG-
IFN based) should be used as first-line therapy are lacking.
Choice of initial therapy should ideally be made considering
the advantages and limitations of available therapy options
and individual patient preferences.
In this review, we assess the pros and cons of the use of
PEG-IFNas a first-line treatment option inchronic hepatitis B
inthelightofrecentadvancesthathavebeenmadeinthefield.
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Because complete eradication of the hepatitis B virus is only
scarcely, if ever, achieved with currently available agents, the
main goal of therapy is to halt the progression of liver
inflammation to fibrosis, cirrhosis, or hepatocellular carcino-
ma [5]. Because these outcomes may not transpire until after
decades of infection, surrogate measures are pursued during
treatment. The most widely used end points of therapy are a
reduction of HBV DNA to undetectable levels (virologic
response), loss of hepatitis B early antigen (HBeAg) with or
without the appearance of anti-HBe (serologic response),
normalization of alanine transaminase (ALT) (biochemical
response), and improvement of liver histology [6]. Sustained
remission of the disease, whether treatment induced or not, is
heralded by a loss of hepatitis B surface antigen (HBsAg)
from serum accompanied by appearance of anti-HBs [7].
Both treatment modalities for chronic hepatitis B infection,
NA and PEG-IFN, affect the host-virus equilibrium in different
ways. PEG-IFN has an immunomodulatory and a direct
antiviral effect, whereas NAs impede viral polymerase activity
and prohibit viral replication [8]. These differences are
reflected in the varying efficacy measures used during therapy.
In HBeAg-positive chronic hepatitis B patients treated
with PEG-IFN, loss of HBeAg from serum accompanied by
the appearance of anti-HBe (HBeAg seroconversion) is the
primary treatment end point, because it is associated with a
high probability of HBsAg seroconversion and increased
survival [4, 6, 9–11]. In addition to HBeAg seroconversion,
suppression of HBV DNA to undetectable levels until
HBeAg seroconversion occurs is often used as efficacy
measure for NA-based therapy.
In HBeAg-negative chronic hepatitis B, suppression of
HBV DNA to low or undetectable levels with normalization
of ALT is currently the treatment goal of choice. Trials
involving PEG-IFN have used, for unclear reasons, 20,000
copies/mL and ALT normalization as primary outcome
measure [12], whereas trials investigating the potency of
NA use improvement in liver histology and HBV DNA
undetectability as primary outcome. Recent insight into the
excellent prognosis of inactive hepatitis B carriers has led to
the use of these criteria (HBV DNA <2,000 IU/mL and ALT
normalization) as response parameters for PEG-IFN therapy
in HBeAg-negative chronic hepatitis B [13￿].
The disparities between treatment outcomes used for NA
and PEG-IFN therapy show an important difference in
treatment approach: during PEG-IFN treatment, viral
suppression is secondary to achieving immunologic control
over the virus and attaining a post-therapy sustained
response. During treatment with NA, achievement of on-
treatment maintained viral suppression to undetectable
levels is always essential, for persisting viral replication
will inevitably lead to resistance [2].
Otherimportant considerationsare the difficulties thatarise
when the effect of treatment on surrogate markers is
extrapolated toclinicaloutcomes. Although sustainedHBeAg
and HBsAg seroconversion are associated with increased
survival and lower incidence of hepatocellular carcinoma [10,
14, 15], an advantageous effect of viral load reduction by
NAwithout sustained HBeAg or HBsAg seroconversion has
only been shown convincingly in patients with advanced
liver disease and is otherwise unclear [9, 16]. In addition,
viral covalently closed circular (ccc-)DNA, the viral replica-
tive intermediate at the basis of hepatitis B virus infection,
persists in host cells even if HBV DNA levels are adequately
suppressed [17]. Consequently, sustained off-treatment tran-
sition to the inactive carrier state should be used as primary
end points during therapy for both HBeAg-positive and
HBeAg-negative chronic hepatitis B. If this end point cannot
be achieved, therapy-maintained HBV DNA suppression to
undetectable levels is a secondary option.
HBeAg-Positive Chronic Hepatitis B
Patients with chronic hepatitis B may present in any one of
four, not necessarily sequential, stages of infection. HBeAg-
positive chronic hepatitis B is regarded as the earliest phase of
infection, and patients commonly present with HBV DNA
levels exceeding 20,000 IU/mL and with either normal or
elevated ALT levels depending on whether the patient is in the
immune tolerant or immune clearance phase of infection [10].
Current European Association for the Study of the Liver
(EASL) and American Association for the Study of Liver
Diseases (AASLD) guidelines propose active therapy of
HBeAg-positive chronic hepatitis B patients who present with
serum HBV DNA levels of over 2,000 IU/mL (20,000 IU/mL
for AASLD) and elevated ALT levels or when liver biopsy
shows at least moderate inflammation or fibrosis. The
primary goal of therapy is achievement of HBeAg serocon-
version and undetectable HBV DNA levels [4, 6].
All registered agents have been evaluated in large
multinational randomized trials for treatment duration of 48–
52 weeks; the serologic response rates are summarized in
Table 1. After 1 year of treatment with PEG-IFN α-2b, 25%
of patients achieved HBeAg seroconversion [18], whereas
this was 27% in patients treated with PEG-IFN α-2a [19].
Six months after discontinuation of treatment, the rates were
29% and 32%, respectively. The ultimate surrogate end point
of therapy, loss of HBsAg with appearance of anti-HBs,
occurred in 4–6% of patients after 1 year of treatment and
6 months of post-treatment follow-up [18, 19]. In both
studies, the addition of lamivudine to PEG-IFN monotherapy
did not increase response rates, although on-treatment viral
suppression was more vigorous in patients who received
combination therapy [18, 19]. A representative cohort of 172
92 Curr Hepatitis Rep (2010) 9:91–98patients treated with PEG-IFN α-2b ± lamivudine in the
aforementioned study were enrolled in a subsequent follow-
up study and revisited after a mean of 3 years. HBeAg
seroconversion was sustained in 70%, and 11% of patients
were HBsAg negative at the end of follow-up [20￿].
ThefiveNAregisteredforchronichepatitisBhaveallbeen
evaluated in large registration trials. Some (lamivudine,
adefovir) against placebo, others (telbivudine, entecavir)
against lamivudine or adefovir (tenofovir). The primary
outcome in all studies was either improvement in Knodell
inflammatory score at the end of treatment or a composite end
point of HBV DNA suppression and improvement in Knodell
score. The five agents differ considerably in their potency
against the hepatitis B virus. Lamivudine suppresses HBV
DNA to undetectable levels in 40% after 1 year of treatment
[19], adefovir in 21% [21], telbivudine in 60% [22], entecavir
in 67% [23], and tenofovir in 76% [24]. Because inclusion
criteria differed between studies, and head-to-head compar-
isons between most agents are lacking, differences in
antiviral potency should be interpreted with caution. Never-
theless, HBeAg seroconversion rates are rather homoge-
neous; approximately 20% of patients show HBeAg
seroconversion after 1 year of treatment regardless of which
NAwas used (Table 1). HBeAg seroconversion rates increase
during prolonged treatment with NA, reaching approximately
28% after 2 years of treatment with lamivudine, entecavir or
tenofovir [25–27]. HBsAg seroconversion is rare during
treatment with NA, in the order of 0% to 2% after 1 year of
therapy, with an exception of 3% for tenofovir [24].
The durability of NA induced HBeAg seroconversion is
doubtful, for studies report that HBeAg seroconversion is
sustained in only 56–64% if treatment is stopped after
lamivudine-induced seroconversion [28, 29]. Theoretically,
NA therapy may be prolonged indefinitely, because side
effects of treatment are generally mild during the first years
of therapy [30]. However, prolongation of treatment comes
at a price, because resistance rates increase with longer
treatmentduration:from14%duringthefirstyearoftreatment
with lamivudine to 69% after 5 years of therapy. Resistance
rates are lower for the most potent NA: 1.2% after 5 years of
therapy with entecavir in treatment-naïve patients and 0%
through 3 years of therapy with tenofovir. However, data
beyond these time points are lacking and the safety of
extended therapy remains to be determined [2].
HBeAg-Negative Chronic Hepatitis B
After loss of HBeAg from serum, viral replication may persist
because of the presence of mutations in the viral genome. The
most commonly encountered mutation is located within the
pre-core region and prohibits the synthesis of HBeAg [10].
Current EASL and AASLD guidelines propose to consider
active therapy of HBeAg-negative patients who present with
levels of serum HBV DNA over 2,000 IU/mL with elevated
ALT levels or when liver biopsy shows at least moderate
inflammation or fibrosis [4]. Patients with HBeAg-negative
chronic hepatitis B commonly present with slightly lower
levels of HBV DNA and only moderately elevated levels of
ALT when compared to HBeAg-positive patients. Because
HBeAg seroconversion is no longer a feasible end point of
therapy, suppression of viral replication, normalization of
ALT, and ultimately HBsAg seroconversion are primary
treatment outcomes [6, 10].
Table 1 Response rates for PEG-IFN and nucleos(t)ide analogues








PEG-IFN 27% 32% 70% 36% 36% 43%
Tenofovir 21% –– 93% ––
Entecavir 21% 17% – 90% 3% –
Adefovir 18% –– 63% ––
Telbivudine 23% –– 88% ––
Lamivudine 20% 19% 64% 72% 7% 13%
Response rates per agent for HBeAg-positive and HBeAg-negative patients. Response is defined as HBeAg seroconversion in HBeAg-positive
patients and as HBV DNA levels <20,000 combined with ALT normalization in HBeAg-negative patients treated with PEG-IFN. Response in
HBeAg-negative patients treated with nucleos(t)ide analogues is defined as maintained viral suppression to undetectable levels. Data were derived
from different studies, not head-to-head comparisons. Data on long-term sustained response were reported in populations different from those used
to calculate response after 1 year of therapy and 6 months post-treatment
ALT alanine transaminase, HBeAg hepatitis B early antigen, PEG-IFN pegylated interferon
aPercentage of responders for 1 year of therapy
bPercentage of responders at 6 months after discontinuation.
cPercentage of initial responders who sustain response through long-term follow up (>1 year after discontinuation).
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multinational registration trials. In one such trial, patients
were randomized to receive PEG-IFN α-2a alone, lamivu-
dine alone, or the combination for 48 weeks of therapy.
Patients were subsequently followed up for 24 weeks.
Primary end point was suppression of HBV DNA levels to
below 20,000 copies/mL and normalization of ALT.
Response rate was 36% for the PEG-IFN monotherapy
group both at the end of treatment and after 24 weeks of
follow-up [12]. After 24 weeks of follow-up, 38% of
patients treated with PEG-IFN had HBV DNA levels
<10,000 copies/mL (the level below which the inactive
carrier state is defined) [13￿]. For lamivudine, the response
rates were 69% at end of therapy and 23% after 24 weeks
of follow-up. Addition of lamivudine to PEG-IFN increased
the probability of an end-of-therapy response, but this
difference was not sustained post-treatment [12]. In other
trials, lamivudine treatment resulted in HBV DNA sup-
pression to undetectable levels in 72% [23], adefovir in
63% [24], telbivudine in 88% [22], entecavir in 90% [23],
and tenofovir in 93% [24] after 1 year of therapy (Table 1).
The durability of post-treatment response to NA is
generally low: 24 weeks after treatment discontinuation,
lamivudine-induced HBV DNA undetectability was sus-
tained in only 7% [12] and relapse rates increased further
during prolonged follow-up [6, 31]. Despite the higher
antiviral potency of entecavir, HBV DNA suppression to
undetectable levels is sustained in only 3% of patients after
24 weeks of post-treatment follow-up [32]. By comparison,
response to PEG-IFN, defined as post-treatment sustained
HBV DNA levels <10,000 copies/mL, is durable in up to
43% of initial responders after 3 years of follow-up [13￿].
Adverse Events
PEG-IFN and NA have vastly different side effect
profiles. Treatment with PEG-IFN is associated with
considerable side effects; the most frequently reported
are a flu-like syndrome, headache, myalgia, fatigue, and
local reactions at the injection site [12, 18, 19]. These
symptoms typically present early during therapy, whereas
neuropsychiatric side effects associated with PEG-IFN
use, such as mood changes and irritability without
depression, tend to present in the later stages [33].
Hepatitis flares have been reported to occur during PEG-
IFN therapy. Especially host-induced flares with eleva-
tions in ALT and a decline in HBV DNA levels have been
associated with a favorable outcome [34]. Patients with
decompensated cirrhosis have an absolute contraindication
to PEG-IFN therapy, but among patients with advanced
fibrosis PEG-IFN is generally well-tolerated and effective
[35]. PEG-IFN has mild myelosuppressive effects, but
PEG-IFN-induced neutropenia and thrombocytopenia re-
sult in clinically significant symptoms, including bleeding
and infections, in only a select group of patients [33].
NAs generally have favorable side effect profiles. Theo-
retically, all NA pose a risk of severe adverse events, for most
inhibit not only viral polymerase enzymes but also host DNA
polymerases [36]. Some agents also inhibit human mito-
chondrial DNA polymerases, which may result in a clinical
syndrome including lactic acidosis, neuropathy and myopa-
thy [36]. Fortunately, most NAs have had few adverse events
during the first years of therapy. During a large randomized
trial, adverse events did not occur more frequently during
lamivudine treatment than with placebo [37]a n dt h es i d e
effect profile of entecavir was indistinguishable from that of
lamivudine [38]. Adefovir is known to be nephrotoxic in up
to one third of patients [39] and renal toxicity is also a
problem with tenofovir, although the latter seems relatively
safe during the first year of therapy [24]. Tenofovir has been
used extensively in HIV-treatment and renal toxicity has
been described at length, necessitating creatinine monitoring
especially during prolonged treatment [36]. In general, NA
show favorable side effect profiles in comparison to PEG-
IFN during the first year of therapy, but long-term safety data
for the new agents are lacking.
Predicting Response to PEG-IFN
Because treatment with PEG-IFN is costly, comes with
considerable side effects, and has only limited efficacy, tools
have been devised to select patients with a high probability of
response. So far, prediction of response to PEG-IFN at baseline
has been challenging, which is reflected in the absence of clear
recommendations regarding which patients should be consid-
ered as candidates for PEG-IFN therapy [4, 6]. Analysis of the
two largest trials investigating the efficacy of PEG-IFN in
HBeAg-positive chronic hepatitis B has shown that response
rates are higher in patients with HBV genotype A and B
compared to C and D and in patients with lower baseline
HBV DNA levels or higher baseline ALT levels [18]. These
findings were confirmed when data from the two studies were
pooled and re-analyzed (n=721) [40￿￿]. In addition to HBV
genotype, lower HBV DNA levels, and higher ALT levels,
female sex, older age, and no prior treatment with IFN were
also recognized as significant predictors of response at
baseline. A logistic regression model including these variables
provided good discrimination between responders and non-
responders. The authors advise consideration of PEG-IFN
therapy in HBeAg-positive patients with a baseline probability
of response >30%, calculated using their individualized PEG-
IFN treatment index [40￿￿].
A similar analysis was performed using the data from a
large trial comparing PEG-IFN ± lamivudine with lamivu-
94 Curr Hepatitis Rep (2010) 9:91–98dine alone in HBeAg-negative chronic hepatitis B. Baseline
factors associated with response in this group were similar
to those identified in HBeAg-positive patients: ALT, HBV
DNA level, age, and sex [41].
However, considerable uncertainty remains whether an
individual will actually benefit from PEG-IFN therapy,
even if baseline probability of response is high. Extension
of baseline prediction of response with on-treatment
parameters may help refine individualized treatment deci-
sions. Frequent assessment of HBV DNA levels during
treatment is therefore recommended in recent guidelines
[4]. Different patterns of viral decline during treatment with
PEG-IFN-α2b with or without lamivudine treatment have
been described in HBeAg-positive patients. Nevertheless,
prediction of response based on viral decline during the first
months of therapy is difficult, because on-treatment kinetics
of HBV DNA provide only limited discrimination and
predictive values are low [42].
Because on-treatment HBV DNA kinetics do not
adequately predict response, focus has changed to other
measures of viral replicative status, such as HBeAg and
HBsAg levels in serum. The latter may provide new insight
into the host-virus equilibrium considering its close
correlation with intrahepatic cccDNA levels [17].
Baseline HBsAg levels appear to be similar in
HBeAg-negative patients who show a decline in HBsAg
while on-treatment and those who do not. However,
patients who developed a sustained response to treatment
with PEG-IFN (HBV DNA undetectability 24 weeks
after treatment discontinuation) experienced a significant
decline in HBsAg levels, whereas patients who did not
respond showed little or no decline [43]. Patients who
experienced a decline in HBsAg levels >0.5 logIU/mL
after 12 weeks of treatment had an 89% probability of
sustained response, whereas patients who did not undergo
such a decline had a 90% probability of not responding.
Similar observations were made for a decline of 1 logIU/
mL after 24 weeks of treatment: the positive predictive
value was 92%, the negative predictive value 97%. [43].
However, these results were reported from a small study
including only a limited and possibly selected group of
patients, and should therefore be interpreted with caution.
Other observations were reported after analysis of data
from the PEG-IFN registration trial in HBeAg-negative
subjects. Patients who had a decline in HBsAg level of
less than 0.46 logIU/mL from pretreatment to end of
therapy had a 95% probability of not having a sustained
response 3 years post-treatment. [44￿￿] Definitive data in
HBeAg-positive chronic hepatitis B are still pending, but
preliminary results show considerable promise [45].
Quantification of HBeAg in patients with HBeAg-
positive chronic hepatitis B has also proven worthwhile.
Patients who experience a limited decrease in HBeAg
levels during the first 4–8 weeks of treatment have a
significantly lower chance of HBeAg seroconversion
[46]. These results were confirmed in a large study, which
also showed that quantification of HBeAg may provide
more discriminatory power than HBV DNA levels [47].
Prospective studies are required to confirm these results
and compare the predictive and discriminatory values of
HBeAg and HBsAg kinetics.
Augmenting Response to PEG-IFN
The majority of patients do not experience a sustained
response after 1 year of PEG-IFN therapy; consequently,
investigators have attempted to increase response rates
using alternative administration strategies. Because lower
baseline HBV DNA levels are associated with a higher
probability of response [40￿￿], it has been hypothesized
that lowering HBV DNA levels with NA before com-
mencing PEG-IFN therapy could increase response rates.
So far, results of studies attempting to test this hypothesis
have been conflicting [48, 49], and definitive data from an
adequately powered trials are still awaited. Additionally,
the effects of extending the duration of PEG-IFN therapy
have been investigated in pilot studies, and have shown
hopeful results [50].
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Considerable advances have been made in the treatment of
chronichepatitisBoverthepastdecade. Withtheavailability
of new and highly efficacious agents, the choice of first-line
therapy has become increasingly complex. Both treatment
modalities—NA and PEG-IFN—have substantial advan-
tages and limitations (Table 2). In HBeAg-positive patients,
PEG-IFN results in post-treatment sustained HBeAg sero-
conversion in 32% of patients after 1 year of treatment and
6 months of follow-up [18, 19], and this response is
sustained in more than 70% [20￿]. Response to PEG-IFN
also increases survival and decreases the incidence of
hepatocellular carcinoma [15]. Direct inhibition of viral
polymerases using NA results in viral suppression in most
patients, but HBeAg seroconversion occurs in only 20% of
patients after the first year of therapy, irrespective of
antiviral potency [2]. Although HBeAg seroconversion
rates increase during prolonged treatment and may eventu-
ally equal or surpass those of a 1-year course of PEG-IFN,
cessation of therapy results in relapse in a considerable
proportion of patients [28]. Prolonged therapy also
increases the chance of the emergence of viral mutants
resistant to current NA and the emergence of NA-related
side effects [36]. Sustained serologic response, preferably
after a finite duration of treatment, should therefore be
pursued in HBeAg-positive patients.
InpatientswithHBeAg-negativechronichepatitisB,PEG-
IFN results in suppression of HBV DNA and ALT normal-
ization in 36% of patients after 1 year of treatment [12]. After
6 months of post-treatment follow-up, this percentage is still
36%, but only 43% of these patients will have sustained this
response through 3 years of follow-up [13￿]. The most potent
NAs, entecavir and tenofovir, can suppress HBV DNA levels
to undetectable levels in more than 90% of patients, but only
a few patients sustain the response after 6 months of
treatment discontinuation [32]. Achieving a post-therapy
sustained response thus seems more difficult in HBeAg-
negative patients, but because indefinite treatment is often
required in HBeAg-negative patients treated with NA and
emergence of resistant mutants and side effects of prolonged
NA treatment may occur, PEG-IFN is still a first-line therapy
option for these patients.
Considering that the limited probability of sustained
response to PEG-IFN is offset by high costs and side effects,
o n l yp a t i e n t sw h oh a v eag o o dc h a n c eo fr e s p o n s es h o u l db e
considered for this therapy. A prediction model for HBeAg-
positive patients provides good discrimination between res-
pondersandnon-responders,andmayhelpclinicianstochoose
patients for PEG-IFN therapy based on readily available data
such as genotype, ALT, sex, and HBV DNA levels [40￿￿].
On-treatment monitoring of patients treated with PEG-IFN
using HBV DNA, HBsAg, and perhaps HBeAg levels may
optimize individualized prediction of response and can
help decide which patients are to benefit from (dis-)
continuing PEG-IFN therapy. If patients are not eligible
f o rP E G - I F Nb a s e do nt h e i rb a seline characteristics or
must discontinue for reasons of inadequate response,
patients should be started on NAs that offer the highest
antiviral potency, the least chance of resistance, and a
favorable side effect profile, because prolonged or
indefinite treatment may be necessary.
Additional research will have to show whether alternative
strategies of PEG-IFN administration, such as continuous
subcutaneous dosing, lowering HBV DNA levels using NA
before PEG-IFN is started, or prolonging PEG-IFN therapy
beyond 1 year, will lead to higher rates of sustained response.
Conclusions
The advantages and limitations of PEG-IFN and NA should
be weighed for every individual patient. PEG-IFN offers a
higherchanceofpost-therapysustainedresponseatthecostof
higher treatment price and considerable side effects. NA
provideeasydailyoraldosingandcanmaintainadequateviral
suppression for prolonged periods, but post-treatment sus-
tained response can probably not be achieved in a majority of
patients. Prolonging treatment with NA may enhance chances
of HBeAg and HBsAg seroconversion. We propose that only
patients who have a high baseline probability of response to
PEG-IFN should be considered for this therapy regimen,
because the potential benefits may offset the higher costs and
side effects. Non-eligible patients or non-responders to PEG-
IFN should be treated with the most potent NA, but long-term
or indefinite therapy is often necessary, posing considerable
risk of viral resistance and long-term side effects.
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